Table 3 Factors association with SEMS patency: A univariate and multivariate analyses by cox proportional hazard model

Antiplatelets use

5

4

1.53 (0.54, 4.34)

0.426

Ursodeoxycholic acid use

12

8

1.23 (0.56, 2.71)

0.602

Primary cancer

 Cholangiocarcinoma

5

5

2.2 (0.8, 5.9)

0.117

 Other

26

11

0.8 (0.4, 1.6)

0.485

 Pancreatic cancer

46

21

1

Size of cancer, median (IQR)

3.8 (3.0, 4.8)

4.0 (2.8, 5.1)

1.3 (1.1, 1.5)

0.006

1.20 (1.02, 1.40)

0.025

Length of stricture, median (IQR)

4.0 (3.0, 5.0)

4.0 (2.5, 4.0)

0.9 (0.7, 1.1)

0.231

Current treatment (chemo/ RT/ surgery)

45

27

1.4 (0.7, 3.1)

0.336

Presence of stones or sludge during SEMS placement

10

13

2.86 (1.43, 5.72)

0.003

3.91 (1.74, 8.75)

0.001

Total bilirubin at 1 month after SEMS placement, mg/dL, median (IQR)

1.6 (0.2–23)

1.8 (0.4, 29.3)

1.12 (1.05, 1.19)

0.001

1.14 (1.06, 1.22)

< 0.001

Length of stent

 10–12

1

1

1.35 (0.18, 10.02)

0.767

2.10 (0.27, 16.12)

0.476

 8

9

6

2.57 (1.05, 6.28)

0.039

2.96 (1.06, 8.30)

0.039

 6

67

30

1

1

Liver disease

5

5

2.49 (0.96, 6.45)

0.060

Perioperative bacterial infection

21

12

1.43 (0.72, 2.88)

0.310

Proximal common bile duct

5

3

1.43 (0.43, 4.67)

0.559

Distal common bile duct

66

27

0.49 (0.24, 1.02)

0.056

More than one level of common bile duct obstruction

25

9

1.29 (0.61, 2.74)

0.506

Stent type

 FC-SEMS

8

5

0.54 (0.17, 1.71)

0.295

 PC-SEMS

63

25

0.53 (0.23, 1.22)

0.135

 UC-SEMS

6

7

1

Change of total bilirubin: within 72 h, mg/dL, median (IQR)

-6.1 (-17.7, 3.1)

-2.2 (-15.7, 3.1)

1.04 (0.96, 1.12)

0.315

Change of total bilirubin at 1 month, mg/dL, median (IQR)

-10.5 (-31.4, 6.5)

-4.0 (-27.8, 20.9)

1.03 (0.98,1.07)

0.249

Stent insertion with difficulty

4

6

2.35 (0.98, 5.66)

0.056